Trials / Completed
CompletedNCT00618319
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the effect of BIIB021 on GIST growth and metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB021 | Dose, schedule, and duration specified in protocol |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2008-02-20
- Last updated
- 2015-10-02
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00618319. Inclusion in this directory is not an endorsement.